347 related articles for article (PubMed ID: 32816734)
21. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
Karakonstantis S; Kritsotakis EI; Gikas A
Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
[TBL] [Abstract][Full Text] [Related]
22. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
[TBL] [Abstract][Full Text] [Related]
23. Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.
Jean-Pierre V; Sorlin P; Pantel A; Chiron R; Lavigne JP; Jeannot K; Marchandin H;
Ann Clin Microbiol Antimicrob; 2024 Jun; 23(1):54. PubMed ID: 38886694
[TBL] [Abstract][Full Text] [Related]
24. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
25. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
26. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
27. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.
Bador J; Amoureux L; Blanc E; Neuwirth C
Antimicrob Agents Chemother; 2013 Jan; 57(1):603-5. PubMed ID: 23089757
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.
Jacquier H; Le Monnier A; Carbonnelle E; Corvec S; Illiaquer M; Bille E; Zahar JR; Jauréguy F; Fihman V; Tankovic J; Cattoir V;
Microb Drug Resist; 2012 Aug; 18(4):396-401. PubMed ID: 22335615
[TBL] [Abstract][Full Text] [Related]
29. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Tamma PD; Hsu AJ
J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
[TBL] [Abstract][Full Text] [Related]
30. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
[TBL] [Abstract][Full Text] [Related]
31. An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.
Spencer HK; Spitznogle SL; Borjan J; Aitken SL
Pharmacotherapy; 2020 Sep; 40(9):936-951. PubMed ID: 32687670
[TBL] [Abstract][Full Text] [Related]
32. Carbapenem-hydrolyzing gram-negative bacteria: current options for treatment and review of drugs in development.
Abandeh FI; Drew ME; Sopirala MM
Recent Pat Antiinfect Drug Discov; 2012 Apr; 7(1):19-27. PubMed ID: 22211694
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
Boyle DP; Zembower TR
Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant
Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816722
[No Abstract] [Full Text] [Related]
35.
Gabrielaite M; Nielsen FC; Johansen HK; Marvig RL
Microb Genom; 2021 Jul; 7(7):. PubMed ID: 34232117
[No Abstract] [Full Text] [Related]
36. New Perspectives on Antimicrobial Agents: Cefiderocol.
McCreary EK; Heil EL; Tamma PD
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
[TBL] [Abstract][Full Text] [Related]
37. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
38. Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.
Belcher R; Zobell JT
Pediatr Pulmonol; 2021 Sep; 56(9):3059-3061. PubMed ID: 34215020
[TBL] [Abstract][Full Text] [Related]
39. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
Warner NC; Bartelt LA; Lachiewicz AM; Tompkins KM; Miller MB; Alby K; Jones MB; Carr AL; Alexander J; Gainey AB; Daniels R; Burch AK; Brown DE; Brownstein MJ; Cheema F; Linder KE; Shields RK; Longworth S; van Duin D
Clin Infect Dis; 2021 Oct; 73(7):e1754-e1757. PubMed ID: 33313656
[TBL] [Abstract][Full Text] [Related]
40. Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics.
Clancy CJ; Nguyen MH
Infect Dis Clin North Am; 2022 Dec; 36(4):791-823. PubMed ID: 36328637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
